Mind Medicine (MindMed) Inc MNMD

Alternate Symbol(s): N.MMED.WA | N.MMED.WR | N.MMED.WS | N.MMED

Healthcare

Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).

NDAQ:MNMD - Post by User

Mind Medicine (MindMed) Inc

Bullboard Posts

Post by josameyeron Sep 07, 2011 8:19am

443 Views

Post# 19017029

new results for the contact zone

Long awaited news on the latest drilling at the contact zone .High grade gold assays at the contact zone of the Black Fox complex./ The best hole CF11-245 Indicates 16.18 gpt over 4,6 m including 83,04 gpt over .75 m.To date Brigus has outlined a area of mineralization , approximately 400m in strike length. The zone remains open along strike to the North and open at depth. Drilling is ongoing. Check out the rest of the released results. Cheers Josa.

Bullboard Posts

Nextech CEO provides company update on Amazon deal and more